MedTrace Logo

A First Time in Human (FTIH) Study of GSK3745417 Administered to Participants With Advanced Solid Tumors

NCT03843359 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 97

Last updated 2026-01-08

Study results available
· View outcomes & findings →

Summary

This study aims to evaluate the safety, tolerability, and preliminary clinical activity and establish a recommended dose of GSK3745417 administered alone (Part 1A) or co-administered (Part 2A) with dostarlimab in participants with refractory/relapsed solid tumors. Both parts will consist of a dose escalation phase.

Conditions

  • Neoplasms

Interventions

DRUG

GSK3745417

GSK3745417 will be administered.

DRUG

Dostarlimab

Dostarlimab will be administered.

Sponsors & Collaborators

Principal Investigators

  • GSK Clinical Trials · GlaxoSmithKline

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-03-12
Primary Completion
2024-04-04
Completion
2026-03-31
FDA Drug
Yes

Countries

  • United States
  • Australia
  • Canada
  • France
  • Japan
  • Netherlands
  • South Korea
  • Spain

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03843359 on ClinicalTrials.gov